Meeting
2013 ASCO Annual Meeting
Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
Authors
Rebecca Suk Heist
Massachusetts General Hospital, Boston, MA
Rebecca Suk Heist , Leena Gandhi , Geoffrey Shapiro , Naiyer A. Rizvi , Howard A. Burris III, Johanna C. Bendell , Jose Baselga , Scott B Yerganian , Karl Hsu , Janet Ogden , Loïc Vincent , Oliver von Richter , Giuseppe Locatelli , Ekatherine Asatiani , Jeffrey R. Infante
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
PI3-Akt-mTOR Pathway
Clinical Trial Registration Number
NCT01390818
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2530)
DOI
10.1200/jco.2013.31.15_suppl.2530
Abstract #
2530
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Phase I and pharmacokinetics/pharmacodynamics (PK/PD) study of MEK inhibitor, RO4987655, in Japanese patients with advanced solid tumors.
First Author: Yasuhide Yamada
Poster
2020 ASCO Virtual Scientific Program
Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).
First Author: Marwan Fakih
Poster
2020 ASCO Virtual Scientific Program
Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.
First Author: Maliha Nusrat
Poster
2018 ASCO Annual Meeting
A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
First Author: Filip Janku